Invega Trinza (Paliperidone Palmitate) Patent Expiration, LOE Window & CMS Spending
Invega Trinza (Paliperidone Palmitate) by Johnson & Johnson: FDA Orange Book LOE 2041-11-24, 11 AB generics, $1.02B 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N207946 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2041-11-24 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 11 |
| 2024 CMS Total Public Spend | $1.02B |
| 2024 Medicare Part D Spend | $549.8M |
| 2024 Medicaid Spend | $471.2M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 19.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.